¾ÅÉ«ÊÓƵ

A

ARTEMIS

A study comparing Ziltivekimab to placebo, given to patients within 36 hours of a heart attack, followed by a monthly injection of the study medication. The study will recruit 10,000 patients over 25 months, in over 630 centres worldwide. 

We are actively recruiting patients for this study. 

B

BEST-INT2D

A randomised interventional trial to establish the impact of prasugrel versus aspirin on the inflammatory and thrombotic effects of hypoglycemia in patients with type 2 diabetes. We are running this study alongside the Diabetic Research Team at ¾ÅÉ«ÊÓƵ Teaching Hospitals. We hope to facilitate the benefits of intensive glycaemic control in type 2 diabetic patients, whilst protecting against the harmful cardiovascular effects of hypoglycaemia.

The study is actively recruiting. 

C

CLARITY PAD

A study to investigate the effectiveness of three antithrombotic regimens following lower-limb revascularisation for chronic limb-threatening ischaemia. The study is being run across 20 sites in the UK, including here in ¾ÅÉ«ÊÓƵ. 

We are actively recruiting for this study. 

COMPLETE-2

Patients with a heart attack and multivessel coronary artery disease are randomised to either physiology-guided or angiography-guided revascularisation of non-culprit lesions. Our team will follow up on patients for an estimated 3.5 years. 

The study is being conducted in approximately 140 centres worldwide. 

CVRU-Obs

An observational study profiling thrombo-inflammatory parameters in patients with or at risk of cardiovascular disease. Patients for this study kindly agree to have an additional blood sample taken, along with a bleeding time measurement. The blood sample is processed in our specialised laboratory, characterising platelet function and the effects of antiplatelet medication. 

H

HORIZON

A double-blind study to examine the impact on clinical outcomes of a novel injectable oligonucleotide, pelacarsen, assessing the effectiveness of lowering Lp(a) in patients with a history of cardiovascular disease.

Patients are currently under follow-up for this study, with a monthly injection administered for the remainder of the study period.

M

MK0616-015

A study to evaluate efficacy and safety of study medication, MK0616 versus placebo, in reducing major adverse cardiovascular events in participants at high risk of further events. MK0616 is PCSK9 inhibitor which results in the reduction of LDL cholesterol. 

The study is being conducted in approximately 600 centres worldwide. We are actively recruiting for this study until June 2025. Patients with a history of heart attacks with high cholesterol may be suitable for this study.

O

ORION-4

A randomised trial to assess the effects on clinical outcomes of cholesterol-lowering injectable, inclisiran, among patients with a history of cardiovascular disease. Recruitment for this study has now ceased, although patients return to clinic for a 6-monthly injection.

S

SOS-AMI

A randomised controlled study to evaluate the efficacy and safety of the self-administered subcutaneous P2Y₁₂ inhibitor selatogrel in patients with a recent history of acute myocardial infarction, at risk of having further myocardial infarction. This study is currently actively recruiting. We ask patients to self-inject should further symptoms of a heart attack occur. 

V

VICTORION-1 PREVENT

A multi-centre, multi-country study, enrolling 14,000 patients at high risk of their first cardiovascular event. Patients are randomised to either inclisiran or placebo and receive 6 monthly injections at The Northern General Hospital. The aim is to compare the adverse event rate between the two treatment groups. 

The patients helping us with this study are under follow-up and we are no longer recruiting.